Trevena ( (TRVN) ) has issued an announcement.
Trevena, Inc. is undergoing significant changes amidst financial challenges, including director resignations and cost-cutting measures, while continuing to explore strategic alternatives for its assets. Despite a reverse stock split, the company faced delisting from Nasdaq, moving its stock to OTC Pink Sheets. The company reported a reduced third-quarter loss and maintains its focus on CNS disorder treatments, with OLINVYK and investigational drugs like TRV045 being central to its pipeline.
For detailed information about TRVN stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Icahn to Boost Stake in CVR Energy to 81% by Cutting IEP’s Dividend
- Amazon Considers Additional Multi-Billion Dollar Investment in Anthropic
- Will Palantir Stock Crash by 50%? Here’s What Jefferies Expects
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
